STAT@AACR: Outsmarting Cancer

This Event has Passed

Where

The Lane
900 Bayfront Ct, Suite 200
San Diego, CA 92101

When

{{getUserDateTimezone("1776819600").singleDate}}
{{getUserDateTimezone("1776819600").time}} - {{getUserDateTimezone("1776830400").time}} {{getClientTimezoneName()}}

About

The American Association for Cancer Research’s annual meeting is a hotbed of data on the cutting edge of cancer: new targeted therapies, new approaches, and new ways of monitoring and diagnosing the disease. Join STAT and leading experts in the field for a deep dive into the biggest stories in oncology research. Drinks and light bites will be served.

The listed time reflects your local time; this event runs 6–9 p.m. PT.

Agenda Highlights

The State of Oncology

Join three of the top oncologists in the world, including two AACR presidents – about the headline-grabbing results presented at the conference and everything from early-stage cancer drug development to promising new ideas for clinical trials to the hard realities and big opportunities in cancer research and the practice of medicine.

Keith T. Flaherty, M.D., FAACR, president, American Association for Cancer Research; director of clinical research, Massachusetts General Cancer Center; professor of medicine, Harvard Medical School
Lillian L. Siu, M.D., FAACR,past president, American Association for Cancer Research; Director, Phase I Clinical Trials Program; Codirector, Robert and Maggie Bras and Family Drug Development Program; Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre; University Health Network; Professor of Medicine, University of Toronto
Robert A. Winn, M.D., director, VCU Massey Comprehensive Cancer Center
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Shifting the Paradigm for Pediatric Cancer | Sponsor Session

The next generation of pediatric cancer treatments is emerging from fundamental discoveries about cancer’s vulnerabilities. Here’s what’s required to translate those insights into therapies that reach patients.

Charles W.M. Roberts, M.D., Ph.D., EVP and director, St. Jude Comprehensive Cancer Center, (sponsor speaker)
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

The KRAS Revolution

A decade after researchers first unlocked the defenses of a so-called “undruggable” form of cancer, the field is on the brink of another breakthrough. Hear from a pioneer in KRAS research about the next wave of targeted medicines, including one that promises to change the standard of care for pancreatic cancer, where new options are desperately needed.

Gregory Verdine, M.D., founder, president, and CEO, LifeMine Therapeutics
Angus Chen, cancer reporter, STAT (moderator)

AstraZeneca’s Next Frontier

AstraZeneca transformed itself from an oncology afterthought into a dominant force in cancer drug development. Join the company’s head of cancer research for a dive into drugmaker’s plans to outdo itself in the years to come, including late-breaking data and new technologies deeper in the pipeline.

Susan Galbraith, Ph.D., executive vice-president, oncology R&D, AstraZeneca
Damian Garde, reporter at large, live and feature journalism, STAT (moderator)